Abstract
There are few effective treatment options for metastatic esophagogastric adenocarcinomas after progression on second-line chemotherapy. Immune checkpoint blockade therapy is a promising treatment strategy for selected advanced esophagogastric cancer, and the PD-1 inhibitor pembrolizumab has recently been approved for metastatic or recurrent gastric or gastroesophageal junction cancer that has progressed beyond second-line systemic therapy. We review the current data supporting immune checkpoint blockade therapy in advanced esophagogastric adenocarcinoma.
Keywords:
PD-1; checkpoint inhibitor; gastric; gastroesophageal; immunotherapy.
© 2018 Wiley Periodicals, Inc.
MeSH terms
-
Adenocarcinoma / immunology
-
Adenocarcinoma / pathology
-
Antibodies, Monoclonal / therapeutic use*
-
B7-H1 Antigen / antagonists & inhibitors
-
B7-H1 Antigen / immunology
-
CTLA-4 Antigen / antagonists & inhibitors
-
CTLA-4 Antigen / immunology
-
Esophagogastric Junction / immunology
-
Esophagogastric Junction / pathology*
-
Humans
-
Immunotherapy
-
Programmed Cell Death 1 Receptor / antagonists & inhibitors
-
Programmed Cell Death 1 Receptor / immunology
-
Randomized Controlled Trials as Topic
-
Stomach Neoplasms / drug therapy*
-
Stomach Neoplasms / immunology
-
Stomach Neoplasms / pathology*
Substances
-
Antibodies, Monoclonal
-
B7-H1 Antigen
-
CD274 protein, human
-
CTLA-4 Antigen
-
CTLA4 protein, human
-
PDCD1 protein, human
-
Programmed Cell Death 1 Receptor